WANTAI BIOLOGICAL(603392)2023-03-20 16:00Financial Performance - The net profit attributable to the parent company for 2022 was CNY 1,437,901,441.50, while the consolidated net profit attributable to shareholders of the listed company was CNY 4,735,795,243.51[4]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% growth compared to the previous year[13]. - In 2022, the company's operating revenue reached ¥11,185,188,715.34, representing a year-over-year increase of 94.51% compared to ¥5,750,329,074.69 in 2021[20]. - The net profit attributable to shareholders was ¥4,735,795,243.51 in 2022, up 134.28% from ¥2,021,467,667.66 in 2021[20]. - The net cash flow from operating activities increased by 145.70% to ¥4,132,592,572.73 in 2022, compared to ¥1,681,947,606.84 in 2021[20]. - Basic earnings per share rose to ¥5.31 in 2022, a significant increase of 130.87% from ¥2.30 in 2021[21]. - The company's total assets grew by 130.34% to ¥16,229,516,571.12 at the end of 2022, compared to ¥7,045,948,104.34 at the end of 2021[20]. - The net assets attributable to shareholders increased by 176.32% to ¥12,341,257,272.74 at the end of 2022, up from ¥4,466,287,176.41 at the end of 2021[20]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 10 per 10 shares (including tax) and to convert 4 shares from capital reserves for every 10 shares held[4]. - The total number of shares eligible for dividend distribution is 904,485,385, resulting in a total cash dividend distribution of CNY 904,485,385.00 (including tax)[4]. - The cash dividend accounts for 100% of the profit distribution for the period, representing 76.83% of the net profit of the parent company and 23.33% of the consolidated net profit attributable to ordinary shareholders[4]. - The company repurchased shares amounting to CNY 200,167,849.00 during the reporting period, which will be included in the total profit distribution calculation[4]. Research and Development - Investment in R&D increased by 30%, focusing on the development of new vaccines and diagnostic products[13]. - The company has a strong R&D team and has invested significantly in innovation, ensuring continuous product development and technological advancement[56]. - The company is focusing on the development of third-generation vaccines, including recombinant subunit vaccines and mRNA vaccines[52]. - The company has established several research centers in collaboration with universities and health organizations to enhance its R&D capabilities[108]. - The company is actively pursuing new product development and market expansion strategies to strengthen its competitive position in the diagnostics industry[101][102]. Market Expansion and Product Development - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[13]. - A strategic acquisition of a local biotech firm was completed, expected to enhance the company's product portfolio and market reach[13]. - The company is focusing on expanding its presence in international markets, with new product registrations in countries like Nepal and Morocco for its HPV vaccine[102]. - The company is actively introducing advanced international testing technologies into China, including partnerships with foreign companies for diagnostic reagent development[46]. - The company aims to launch several new vaccines within the next 5 to 10 years, including the varicella vaccine, 9-valent HPV vaccine, and 20-valent pneumococcal vaccine, among others[136]. Compliance and Governance - The company received a standard unqualified audit report from Rongcheng Accounting Firm[3]. - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[5]. - The company strictly adheres to the requirements of the Company Law, Securities Law, and other relevant regulations to enhance information disclosure and improve corporate governance structure[152]. - The supervisory board ensures compliance and legality in the company's financial and operational activities, fulfilling its responsibilities diligently[153]. Environmental Responsibility - The company invested 1,000,000 RMB in environmental protection during the reporting period[190]. - The wastewater treatment facility has a capacity of 500 m³/d and meets the discharge standards for pollutants[192]. - The company has established an emergency response plan for environmental incidents, which was filed with the ecological environment bureau[194]. - The company has implemented effective noise reduction measures in its facilities, minimizing the impact of noise pollution from equipment such as gas boilers and air conditioning units[199]. - The company has not faced any legal penalties for environmental violations, demonstrating compliance with environmental regulations[200]. Employee and Management Structure - The company employed 4,016 staff as of December 31, 2022, an increase of 913 from the previous year, with 1,259 in R&D roles[44]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 10.2361 million[163]. - The company has a diverse management team with extensive experience in various sectors, enhancing its operational capabilities[161]. - The company emphasizes the importance of performance-based remuneration to align the interests of management with those of shareholders[163]. - The company has established a training management standard to enhance employee skills and knowledge[179].